bevacizumab (hereditary hemorrhagic telangiectasia, Hospices Civils De Lyon)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug Namebevacizumab (hereditary hemorrhagic telangiectasia, Hospices Civils De Lyon)
Drug Alias NameBevacizumab (hereditary hemorrhagic telangiectasia, Hospices Civils De Lyon)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsTelangiectasia, Hereditary Hemorrhagic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHospices Civils De Lyon
China Registration ClassN/A

Develop Information

Active CompaniesHospices Civils De Lyon
Inactive CompaniesN/A
Active IndicationsTelangiectasia, Hereditary Hemorrhagic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A